Diet Pills: The Future
Diet Pills: The Future’
The quest for the perfect weight loss drug continues as the prevalence of obesity in the United States and other industrialized
countries rises.Why has it been so difficult for drug manufacturers to develop the “perfect” diet pill? One reason is that the causes of obesity are not [...]
Dietary Supplements stimulants for Weight Loss
Dietary Supplements stimulants for Weight Loss
With the withdrawal of ephedra from the U.S. market, companies producing dietary supplements for weight loss have replaced ephedra with other stimulants to induce weight loss. Many of these stimulants contain caffeine or are very similar to caffeine. Caffeine and related substances suppress appetite and cause increased [...]
Study: Acomplia Increases the Likelihood of Success in Quitting Smoking
Researchers at the University of Cincinnati Acomplia (rimonabant) College of Medicine presented results of one of the largest smoking cessation trials ever conducted in the United States, STRATUS-US (STudies with Rimonabant And Tobacco USe). The findings show that a new drug, rimonabant, doubled the odds of quitting smoking compared [...]
Causes of Obesity-Environmental Factors
Causes of Obesity-Environmental Factors
Along with genetics, environmental factors have been found to contribute to obesity. In particular, increased food consumptionand an inactive (sedentary) lifestyle are environmental factors that very closely correlate with an increased risk of obesity.Americans have an ever-increasing number of energydense foods, packaged in enormous portions, conveniently available at low [...]
Quitting smoking rimonabant
Quitting smoking rimonabantQuitting smoking is difficult, and the fact that quitting smoking often leads to unhealthy weight gain is often a justification for people to delay their attempts to break free from their habit.
Smoking is the leading preventable cause of death in the world today, and if [...]
Regulators Will Be Wary in Weighing Up Acomplia
The Guardian, in the following story published on January 10, 2005, says that while Sanofi is confident it has a winner in the new anti–obesity drug Acomplia, it can expect close scrutiny during the approval process of the side effects.
Want to lose weight, stop smoking and cut [...]
Obesity Expert Hails Acomplia Trial Results as Potentially “Major Advance”
Dr Nick Finer, consultant in obesity medicine at Addenbrooke’s Hospital in Cambridge Acomplia (rimonabant) , who was involved in the study on diabetic patients, said the drug “could be a major advance in the management, not just of obesity, but of the risk factors of obesity”.
[...]
New Patients Sought for Study of Acomplia Role in Curbing Alcohol Consumption
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is continuing to seeking volunteers for a Phase II clinical trial exploring the potential of the promising obesity drug Acomplia (rimonabant) (rimonabant) in curbing alcohol consumption.
A spokesperson for NIAAA said the trial of “Rimonabant to Reduce Alcohol Consumption,” [...]
